10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems.
Excellent balance sheet with limited growth.
Share Price & News
How has 10x Genomics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: TXG's share price has been volatile over the past 3 months.
7 Day Return
US Life Sciences
1 Year Return
US Life Sciences
Return vs Industry: Insufficient data to determine how TXG performed against the US Life Sciences industry.
Return vs Market: Insufficient data to determine how TXG performed against the US Market.
Price Volatility Vs. Market
How volatile is 10x Genomics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
Is 10x Genomics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate TXG's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate TXG's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: TXG is unprofitable, so we can't compare its PE Ratio to the Life Sciences industry average.
PE vs Market: TXG is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate TXG's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: TXG is overvalued based on its PB Ratio (21.1x) compared to the US Life Sciences industry average (5.8x).
How is 10x Genomics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TXG is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: TXG is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: TXG is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: TXG's revenue (34.6% per year) is forecast to grow faster than the US market (7.6% per year).
High Growth Revenue: TXG's revenue (34.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: TXG is forecast to be unprofitable in 3 years.
How has 10x Genomics performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: TXG is currently unprofitable.
Growing Profit Margin: TXG is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if TXG's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare TXG's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TXG is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (16.6%).
Return on Equity
High ROE: TXG has a negative Return on Equity (-23.64%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is 10x Genomics's financial position?
Financial Position Analysis
Short Term Liabilities: TXG's short term assets ($474.1M) exceed its short term liabilities ($48.2M).
Long Term Liabilities: TXG's short term assets ($474.1M) exceed its long term liabilities ($103.1M).
Debt to Equity History and Analysis
Debt Level: TXG's debt to equity ratio (7%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if TXG's debt to equity ratio has reduced over the past 5 years.
Inventory Level: TXG has a low level of unsold assets or inventory.
Debt Coverage by Assets: TXG's debt is covered by short term assets (assets are 16x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TXG has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: TXG has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -49.7% each year
What is 10x Genomics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate TXG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate TXG's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if TXG's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TXG's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of TXG's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Serge Saxonov (42yo)
Dr. Serge Saxonov Co-Founded 10X Genomics, Inc. and has been its Chief Executive Officer and Director since July 2012. Prior to 10x Genomics, Dr. Saxonov was Vice President of Applications at QuantaLife, w ...
CEO Compensation Analysis
Compensation vs Market: Serge's total compensation ($USD1.08M) is below average for companies of similar size in the US market ($USD6.26M).
Compensation vs Earnings: Insufficient data to compare Serge's compensation with company performance.
|Chief Financial Officer||1.3yrs||US$1.74m||no data|
|General Counsel||2.6yrs||US$874.78k||0.087% $7.6m|
|Co-Founder||7.6yrs||no data||3.19% $276.8m|
|Vice President of Operations||0yrs||no data||no data|
|Vice President of Global Support & Sales Operations||3.4yrs||no data||no data|
|Senior Vice President of Global Sales||1.1yrs||no data||no data|
|Chief People Officer||1.8yrs||no data||no data|
|Senior Vice President of R&D & Founding Scientist||1.1yrs||no data||no data|
|Senior Vice President of Product||1.1yrs||no data||no data|
Experienced Management: TXG's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
|Co-Founder||7.6yrs||no data||3.19% $276.8m|
|Independent Director||6.3yrs||no data||no data|
|Independent Director||0.5yrs||no data||no data|
|Independent Director||2.5yrs||no data||no data|
|Independent Director||0.8yrs||no data||0.011% $977.0k|
Experienced Board: TXG's board of directors are considered experienced (6.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: TXG only recently listed within the past 12 months, with total shares outstanding growing by 42.4% in the past year..
10x Genomics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: 10x Genomics, Inc.
- Ticker: TXG
- Exchange: NasdaqGS
- Founded: 2012
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$8.676b
- Shares outstanding: 96.17m
- Website: https://www.10xgenomics.com
Number of Employees
- 10x Genomics, Inc.
- 6230 Stoneridge Mall Road
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|TXG||NasdaqGS (Nasdaq Global Select)||Yes||Class A Common Stock||US||USD||Sep 2019|
|1KJ||BST (Boerse-Stuttgart)||Yes||Class A Common Stock||DE||EUR||Sep 2019|
|1KJ||DB (Deutsche Boerse AG)||Yes||Class A Common Stock||DE||EUR||Sep 2019|
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems. It offers chromium instruments, enzymes, reagents, microfluidic chips, and other consumable products, as well as software for analyzing biological systems. The company serves researchers in approximately 40 countries. Its customers include a range of academic, government, biopharmaceutical, biotechnology, and other institutions worldwide. 10X Genomics, Inc. was formerly known as 10X Technologies, Inc. and changed its name to 10X Genomics, Inc. in November 2014. The company was incorporated in 2012 and is based in Pleasanton, California.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/19 02:36|
|End of Day Share Price||2020/02/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.